Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trialMiriam Santer, Alison Layton, Paul Little et al.|BMJ|2023Cited by 60
Spironolactone for adult female acne (SAFA): protocol for a double-blind, placebo-controlled, phase III randomised study of spironolactone as systemic therapy for acne in adult womenSusanne Renz, Miriam Santer, Fay Chinnery et al.|BMJ Open|2021Cited by 17
Patient-reported outcome measures for acne: a mixed-methods validation study (acne PROMs)Samantha Hornsey, Miriam Santer, Beth Stuart et al.|BMJ Open|2021Cited by 12
Clinical and cost-effectiveness of spironolactone in treating persistent facial acne in women: SAFA double-blinded RCTMiriam Santer, Alison Layton, Megan Lawrence et al.|Health Technology Assessment|2024Cited by 7
Cost-effectiveness of Spironolactone for Adult Female Acne (SAFA): economic evaluation alongside a randomised controlled trialSarah Pyne, Miriam Santer, Tracey Sach et al.|BMJ Open|2023Cited by 5